| Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients S Abdul-Jawad, L Baù, T Alaguthurai, IDM Del Barrio, AG Laing, ... Cancer cell 39 (2), 257-275. e6, 2021 | 110 | 2021 |
| Perspectives on the treatment of malignant pleural mesothelioma SM Janes, D Alrifai, DA Fennell New England Journal of Medicine 385 (13), 1207-1218, 2021 | 101 | 2021 |
| Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours A Childs, A Kirkwood, J Edeline, TV Luong, J Watkins, A Lamarca, ... Endocrine-related cancer 23 (7), 563-570, 2016 | 37 | 2016 |
| Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells KK Kolluri, C Alifrangis, N Kumar, Y Ishii, S Price, M Michaut, S Williams, ... Elife 7, e30224, 2018 | 34 | 2018 |
| A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations D Alrifai, S Popat, M Ahmed, D Gonzalez, AG Nicholson, J du Parcq, ... Lung Cancer 80 (3), 339-340, 2013 | 33 | 2013 |
| Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi … P Patel, D Alrifai, F McDonald, M Forster, AstraZeneca UK Limited British Journal of Cancer 123 (Suppl 1), 18-27, 2020 | 14 | 2020 |
| Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma N Kumar, D Alrifai, KK Kolluri, EK Sage, Y Ishii, N Guppy, E Borg, ... Lung Cancer 127, 164-166, 2019 | 13 | 2019 |
| Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells D Alrifai, D Sarker, J Maher Immunopharmacology and immunotoxicology 38 (1), 50-60, 2016 | 11 | 2016 |
| BAP1 and YY1 regulate expression of death receptors in malignant pleural mesothelioma Y Ishii, KK Kolluri, A Pennycuick, X Zhang, E Nigro, D Alrifai, E Borg, ... Journal of Biological Chemistry 297 (5), 2021 | 6 | 2021 |
| Emerging resistance pathways in lung cancer: what has ROS-1 taught us? D Alrifai, MD Forster, SM Janes Translational Lung Cancer Research 7 (Suppl 1), S9, 2018 | 5 | 2018 |
| TACTICAL: A phase I/II trial to assess the safety and efficacy of MSCTRAIL in the treatment of metastatic lung adenocarcinoma. A Davies, B Sage, K Kolluri, D Alrifai, R Graham, B Weil, R Rego, O Bain, ... Journal of Clinical Oncology 37 (15_suppl), TPS9116-TPS9116, 2019 | 3 | 2019 |
| MLN8237 (alisertib) and its role in peripheral T-cell lymphoma D Alrifai, R Pettengell Expert Opinion on Investigational Drugs 23 (12), 1731-1736, 2014 | 3 | 2014 |
| Comparative Evaluation of Machine Learning Algorithms on Lung Cancer Type Classification from DNA Microarray Data FB Ali, D Alrifai, M Braoudaki, S Adeleke, I Mporas 2021 International Conference on Biomedical Innovations and Applications …, 2022 | 1 | 2022 |
| T1 Loss of BAP1 function leads to TRAIL sensitivity in mesothelioma N Kumar, KK Kolluri, C Alifrangis, Y Ishii, S Price, M Michaut, S Williams, ... Thorax 73 (Suppl 4), A1-A1, 2018 | 1 | 2018 |
| The search for viable biochemical and clinical prognostic markers for patients with inoperable melanoma being treated with Anti CTLA-4 therapy J Chow, D Alrifai, A Shields, R Kandassamy, B Tan Annals of Oncology 28, x115, 2017 | 1 | 2017 |
| Immunotherapy Toxicity Prediction in Melanoma Patients Using Machine Learning Algorithms L Sharma, E Mohan, V Balaji, J Wong, A Joshi, I Mporas, J Shi, Y Zhao, ... ASCO 2024 Annual Meeting American Society of Clinical Oncology, 2024 | | 2024 |
| 199P Novel machine learning (ML) algorithm to predict immunotherapy response in small cell (SCLC) and non-small cell (NSCLC) lung cancer L Sharma, S Choi, V Balaji, A Joshi, I Mporas, J Shi, Y Zhao, V Tailor, ... Annals of Oncology 34, S261, 2023 | | 2023 |
| Current Role of Immunotherapy D Alrifai, DP Pastos Academic Press, 2022 | | 2022 |
| Perspectives on the Treatment of Malignant Pleural Mesothelioma D Fennell, SM Janes, D Alrifai University of Leicester, 2021 | | 2021 |
| Enhancing the effect of Tumour necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) in malignant pleural mesothelioma D Alrifai UCL (University College London), 2020 | | 2020 |
